Skip to main content
SpringerLink
Log in

What is the impact of biologicals in colorectal cancer?

  • Review
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

An impressive array of therapeutic biological agents is currently being studied in the treatment of colorectal and other cancers. In advanced colorectal cancer, the majority of evidence currently available supporting the use of biological agents outside clinical trials involves the monoclonal antibodies cetuximab and panitumumab, which are epidermal growth factor receptor (EGFR) inhibitors, and the vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab. Ongoing studies are underway to see if benefits are transferable into the adjuvant setting. The role of small molecules that inhibit the EGFR and VEGF receptors in colorectal cancer is yet to be determined. This article reviews the current clinical evidence regarding the use of biological agents in colorectal cancer and the potential impact on day-to-day management of this common clinical condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237

    Article  PubMed  CAS  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    PubMed  Google Scholar 

  3. Porebska I, Harlozinska A, Bojarowski T (2000) Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 21:105–115

    Article  PubMed  CAS  Google Scholar 

  4. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  PubMed  CAS  Google Scholar 

  5. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  PubMed  CAS  Google Scholar 

  6. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

    Article  PubMed  CAS  Google Scholar 

  7. Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048

    Article  PubMed  CAS  Google Scholar 

  8. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  PubMed  CAS  Google Scholar 

  9. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671–680

    PubMed  CAS  Google Scholar 

  10. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18

    PubMed  CAS  Google Scholar 

  11. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  PubMed  CAS  Google Scholar 

  12. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  13. Saltz LB, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, LoBuglio A (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a (abstract 7)

    Google Scholar 

  14. Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208

    Article  PubMed  CAS  Google Scholar 

  15. Sobrero A, Fehrenbacher L, Rivera F, Steinhauer E, Prausova J, Borg C, Abubakr Y, Zubel A, Langer C, Burris H (2007) Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial. American Association for Cancer Research Annual Meeting Proceedings, 14–18 April, Los Angeles, CA; Abstract 3536, AACR 2007, Philadelphia, PA

  16. Eng C, Maurel J, Scheithauer W et al (2007) Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. J Clin Oncol 25:4003 (Meeting Abstracts)

    Google Scholar 

  17. Lenz HJ, Van Cutsem E, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914–4921

    Article  PubMed  CAS  Google Scholar 

  18. Souglakos J, Kalykaki A, Vamvakas L et al (2007) Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 18:305–310

    Article  PubMed  CAS  Google Scholar 

  19. Polikoff J, Mitchell EP, Badarinath S et al (2005) Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized phase III trial. J Clin Oncol 23:3574 (Meeting Abstracts)

    Google Scholar 

  20. Van Cutsem E, Nowacki M, Lang I et al (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 25:4000 (Meeting Abstracts)

    Google Scholar 

  21. Tabernero J, Van Cutsem E, Diaz-Rubio E et al (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225–5232

    Article  PubMed  CAS  Google Scholar 

  22. Bokemeyer C, Bondarenko I, Makhson A et al (2007) Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 25:4035 (Meeting Abstracts)

    Google Scholar 

  23. Tejpar S, Peeters M, Humblet Y et al (2007) Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), harmacodynamic (PD) and efficacy data. J Clin Oncol 25:4037 (Meeting Abstracts)

    Google Scholar 

  24. Tabernero J, Cervantes A, Martinelli E et al (2006) Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 24:3085 (Meeting Abstracts)

    Google Scholar 

  25. Pippas AW, Lenz HJ, Mayer RJ et al (2005) Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. J Clin Oncol 23:3595 (Meeting Abstracts)

    Google Scholar 

  26. Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810

    Article  PubMed  CAS  Google Scholar 

  27. Scartozzi M, Bearzi I, Berardi R et al (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22:4772–4778

    Article  PubMed  CAS  Google Scholar 

  28. Finocchiaro G, Cappuzzo F, Janne PA et al (2007) EGFR, HER2 and K-ras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 25:4021 (Meeting Abstracts)

    Article  Google Scholar 

  29. Romagnani E, Martin V, Ghisletta M et al (2007) EGFR gene status, K-Ras mutation and PTEN expression predict cetuximab response in metastatic colorectal cancer (mCRC). 2007 Gastrointestinal Cancers Symposium, Orlando, Florida

  30. Di Fiore F, Le Pessot F, Lamy A et al (2007) KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer. J Clin Oncol 25:10502 (Meeting Abstracts)

    Google Scholar 

  31. Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995

    Article  PubMed  CAS  Google Scholar 

  32. Amado RG, Wolf M, Freeman D, Peeters M, Van Cutsem E, Siena S, Suggs S, Patterson S, Chang D: (2007) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer: results from a randomized, controlled trial. 14th European Cancer Conference Proceedings, 23–27 September, Barcelona, Spain; Abstract 0007

  33. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25:4779–4786

    Article  PubMed  CAS  Google Scholar 

  34. Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–3705

    Article  PubMed  CAS  Google Scholar 

  35. Hochster HS, Hart LL, Ramanathan RK et al (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol 24:3510 (Meeting Abstracts)

    Article  Google Scholar 

  36. Hurwitz H, Saini S (2006) Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33:S26–S34

    Article  PubMed  CAS  Google Scholar 

  37. Saltz L, Clarke S, Diaz-Rubio E et al (2007) Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 25:4028 (Meeting Abstracts)

    Google Scholar 

  38. Cassidy J, Clarke S, Rubio ED et al (2006) First efficacy and safety results from XELOX-1/NO16966, a randomised 2 2 factorial phase III trial of XELOX vs. FOLFOX4 1 bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). European Society of Medical Oncology, Istanbul, Turkey

  39. Berry S, Cunningham D, Michael M et al (2007) Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and fluoropyrimidines for mCRC: first BEAT. 14th European Cancer Conference Proceedings, 23–27 September, Barcelona, Spain

  40. Kozloff M, Hainsworth J, Badarinath S et al (2006) Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol 24:3537 (Meeting Abstracts)

    Google Scholar 

  41. Grothey A, Sugrue M, Hedrick E et al (2007) Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). J Clin Oncol 25:4036 (Meeting Abstracts)

    Google Scholar 

  42. Hecht JR, Trarbach T, Jaeger E et al (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 23:LBA3 (Meeting Abstracts)

    Google Scholar 

  43. Koehne C, Bajetta E, Lin E et al (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol 24:3508 (Meeting Abstracts)

    Google Scholar 

  44. Saltz LB, Lenz HJ, Kindler HL et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557–4561

    Article  PubMed  CAS  Google Scholar 

  45. Hecht J, Chidiac T, Mitchell E et al (2007) An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC). Ann Oncol 18:vii21 (abstract 0-0033). Proceedings of the 9th World Congress on Gastrointestinal Cancer

  46. Keilholz U, Arnold D, Niederle N et al (2005) Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial. J Clin Oncol 23:3575 (Meeting Abstracts)

    Article  CAS  Google Scholar 

  47. Townsley CA, Major P, Siu LL et al (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94:1136–1143

    Article  PubMed  CAS  Google Scholar 

  48. Rothenberg ML, LaFleur B, Levy DE et al (2005) Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 23:9265–9274

    Article  PubMed  CAS  Google Scholar 

  49. Mackenzie MJ, Hirte HW, Glenwood G et al (2005) A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 23:165–170

    Article  PubMed  CAS  Google Scholar 

  50. Gelibter AJ, Gamucci T, Pollera CF et al (2007) A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. Curr Med Res Opin 23:2117–2123

    Article  PubMed  CAS  Google Scholar 

  51. Fisher GA, Kuo T, Cho CD et al (2004) A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol 22:3514 (Meeting Abstracts)

    Article  CAS  Google Scholar 

  52. Zampino MG, Magni E, Massacesi C et al (2007) First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 110:752–758

    Article  PubMed  CAS  Google Scholar 

  53. Vincent M, Kerr I, Dingle B et al (2007) Capecitabine (X) compared to X+erlotinib (E) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Interim efficacy results from a randomized phase II study. J Clin Oncol 25:14560 (Meeting Abstracts)

    Google Scholar 

  54. Meyerhardt JA, Stuart K, Fuchs CS et al (2007) Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 18:1185–1189

    Article  PubMed  CAS  Google Scholar 

  55. Spigel DR, Hainsworth JD, Burris HA et al (2006) Phase II study of FOLFOX4, bevacizumab, and erlotinib as first-line therapy in patients with advanced colorectal cancer. Proceedings of the Gastrointestinal Cancers Symposium

  56. Meyerhardt JA, Heseltine D, Ogino S et al (2006) Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 6:59–65

    Article  PubMed  CAS  Google Scholar 

  57. Kuo T, Cho CD, Halsey J et al (2005) Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 23:5613–5619

    Article  PubMed  CAS  Google Scholar 

  58. Veronese ML, Sun W, Giantonio B et al (2005) A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 92:1846–1849

    Article  PubMed  CAS  Google Scholar 

  59. Chau I, Cunningham D, Hickish T et al (2007) Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study. Ann Oncol 18:730–737

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

No external sources of funding were received in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Royal Marsden Hospital London and Surrey, Downs Road, Sutton, SM2 5PT, Surrey, United Kingdom

    Rachel Wong & David Cunningham

Authors
  1. Rachel Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Cunningham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wong, R., Cunningham, D. What is the impact of biologicals in colorectal cancer?. Targ Oncol 3, 59–69 (2008). https://doi.org/10.1007/s11523-008-0074-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-008-0074-9

Keywords

Search

Navigation